Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q3 EPS of ($0.63), $0.14 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $0 versus the consensus estimate of $88.89 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.